News & Updates
Filter by Specialty:
FMT offers no weight loss benefits in individuals with obesity
For individuals with obesity who are scheduled to undergo bariatric surgery, faecal microbiota transplantation (FMT) from a lean donor does not appear to help reduce weight before or after the procedure, according to a study.
FMT offers no weight loss benefits in individuals with obesity
22 Dec 2022
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
22 Dec 2022
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
Exposure to dihydropyridine calcium channel blockers does not appear to put patients at increased risk of developing pancreatic cancer as compared with thiazide diuretics, as shown in a large study.
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
22 Dec 2022
Local data support continuation of RASIs in patients with T2D and advanced CKD
Discontinuation of renin-angiotensin system inhibitors (RASIs) is associated with higher risks of cardiorenal complications and neutral risk of all-cause mortality in patients with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD), according to researchers from the Chinese University of Hong Kong (CUHK).
Local data support continuation of RASIs in patients with T2D and advanced CKD
22 Dec 2022
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
21 Dec 2022
5-fraction SBRT improves outcomes in osseous renal cell carcinoma metastases
Local-control outcomes are encouraging in patients with osseous renal cell carcinoma metastases who went through five fractions of stereotactic body radiotherapy (SBRT), reports a study.